Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 May 1;201(9):1298-302.
doi: 10.1086/651664.

The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection

Martin Markowitz  1 , Florin Vaida, C Bradley Hare, Daniel Boden, Hiroshi Mohri, Frederick M Hecht, Robert C Kalayjian, Ann Conrad, Donna Mildvan, Judith Aberg, Christine Hogan, J Michael Kilby, Henry H Balfour Jr, Kim Schafer, Douglas Richman, Susan Little
Affiliations
Randomized Controlled Trial

The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection

Martin Markowitz et al. J Infect Dis. .

Abstract

Acute human immunodeficiency virus type 1 (HIV-1) infection is characterized by high levels of immune activation. Immunomodulation with cyclosporine combined with antiretroviral therapy (ART) in the setting of acute and early HIV-1 infection has been reported to result in enhanced immune reconstitution. Fifty-four individuals with acute and early infection were randomized to receive ART with 4 weeks of cyclosporine versus ART alone. In 48 subjects who completed the study, there were no significant differences between treatment arms in levels of proviral DNA or CD4(+) T cell counts. Adjunctive therapy with cyclosporine in this setting does not provide apparent virologic or immunologic benefit.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: There are no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Fig. 1a. Longitudinal mean log10 HIV-1 RNA levels in patients completing the study. Fig. 1b. Mean proviral DNA levels expressed as copy number per 106 CD4+ T cells at weeks 12, 24, and 48. Fig. 1c. Longitudinal mean absolute CD4+Tcell counts (cells/mm3). In all panels grey solid lines and circles represent values in patients on Arm A; dashed black lines and black triangles represent values for patients on Arm B. The error bars represent 95% confidence intervals for the mean.
Fig. 1
Fig. 1
Fig. 1a. Longitudinal mean log10 HIV-1 RNA levels in patients completing the study. Fig. 1b. Mean proviral DNA levels expressed as copy number per 106 CD4+ T cells at weeks 12, 24, and 48. Fig. 1c. Longitudinal mean absolute CD4+Tcell counts (cells/mm3). In all panels grey solid lines and circles represent values in patients on Arm A; dashed black lines and black triangles represent values for patients on Arm B. The error bars represent 95% confidence intervals for the mean.
Fig. 1
Fig. 1
Fig. 1a. Longitudinal mean log10 HIV-1 RNA levels in patients completing the study. Fig. 1b. Mean proviral DNA levels expressed as copy number per 106 CD4+ T cells at weeks 12, 24, and 48. Fig. 1c. Longitudinal mean absolute CD4+Tcell counts (cells/mm3). In all panels grey solid lines and circles represent values in patients on Arm A; dashed black lines and black triangles represent values for patients on Arm B. The error bars represent 95% confidence intervals for the mean.
See this image and copyright information in PMC

References

    1. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004;200:749–59. - PMC - PubMed
    1. Mehandru S, Poles MA, Tenner-Racz K, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med. 2004;200:761–70. - PMC - PubMed
    1. Schacker TW, Hughes JP, Shea T, Coombs RW, Corey L. Biological and virologic characteristics of primary HIV infection. Ann Intern Med. 1998;128:613–20. - PubMed
    1. Hoen B, Cooper DA, Lampe FC, et al. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Clin Infect Dis. 2007;45:381–90. - PubMed
    1. Markowitz M, Vesanen M, Tenner-Racz K, et al. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis. 1999;179:527–37. - PubMed

Publication types

MeSH terms